Search Result

Results for "

Hypoxia-inducible factor inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HIF/HIF Prolyl-Hydroxylase (63) ADC Payload (3) Akt (1) Antibiotic (11) Apoptosis (18) Autophagy (2) Bacterial (8) Calcium Channel (7) Caspase (1) Ferroptosis (4) Fungal (3) HSP (3) IKK (1) Influenza Virus (3) Isotope-Labeled Compounds (6) MDM-2/p53 (7) MicroRNA (3) mTOR (1) NF-κB (1) NO Synthase (2) Potassium Channel (7) Reactive Oxygen Species (ROS) (5) Reference Standards (10) TAM Receptor (1) Topoisomerase (3) VEGFR (3)
By Research Areas:	Cancer (47) Cardiovascular Disease (18) Infection (14) Inflammation/Immunology (15) Metabolic Disease (16) Neurological Disease (11)

By Targets:

HIF/HIF Prolyl-Hydroxylase (63)

ADC Payload (3)

Akt (1)

Antibiotic (11)

Apoptosis (18)

Autophagy (2)

Bacterial (8)

Calcium Channel (7)

Caspase (1)

Ferroptosis (4)

Fungal (3)

HSP (3)

IKK (1)

Influenza Virus (3)

Isotope-Labeled Compounds (6)

MDM-2/p53 (7)

MicroRNA (3)

mTOR (1)

NF-κB (1)

NO Synthase (2)

Potassium Channel (7)

Reactive Oxygen Species (ROS) (5)

Reference Standards (10)

TAM Receptor (1)

Topoisomerase (3)

VEGFR (3)

By Research Areas:

Cancer (47)

Cardiovascular Disease (18)

Infection (14)

Inflammation/Immunology (15)

Metabolic Disease (16)

Neurological Disease (11)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: HIF/HIF Prolyl-Hydroxylase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13426

Roxadustat 55+ Cited Publications FG-4592	HIF/HIF Prolyl-Hydroxylase Ferroptosis	Infection Cancer
Roxadustat is an orally active hypoxia-inducible factor prolyl-hydroxylase (PHD) inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin .

HY-16560

Camptothecin 65+ Cited Publications Campathecin; (S)-(+)-Camptothecin; CPT	Topoisomerase ADC Payload MicroRNA Influenza Virus Apoptosis Fungal Antibiotic	Infection Cancer
Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM . Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells .

HY-17412

Minocycline hydrochloride 60+ Cited Publications	Bacterial Antibiotic HIF/HIF Prolyl-Hydroxylase Apoptosis MDM-2/p53 Potassium Channel Calcium Channel	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Minocycline hydrochloride is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline hydrochloride is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline hydrochloride shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline hydrochloride reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline hydrochloride inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-15836

BAY 87-2243 25+ Cited Publications	HIF/HIF Prolyl-Hydroxylase Ferroptosis	Cancer
BAY 87-2243 is a highly potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor.

HY-17608

Daprodustat 15+ Cited Publications GSK1278863	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Daprodustat (GSK1278863) is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor being developed for the treatment of anemia associated with chronic kidney disease.

HY-109057

Enarodustat 4 Publications Verification JTZ-951; SAL0951	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
Enarodustat is a potent and orally active hypoxia-inducible factor prolyl hydroxylase inhibitor, with an EC₅₀ of 0.22 μM. Enarodustat has the potential for renal anemia treatment.

HY-12654

Molidustat 5+ Cited Publications BAY 85-3934	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Molidustat (BAY 85-3934) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC₅₀ values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat can be utilized in the research of renal anemia .

HY-17412A

Minocycline 60+ Cited Publications	Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase Apoptosis MDM-2/p53 Potassium Channel Calcium Channel	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-18777

KC7F2 15+ Cited Publications	HIF/HIF Prolyl-Hydroxylase	Cancer
KC7F2 is a potent hypoxia inducible factor-1 (HIF-1) pathway inhibitor with an IC₅₀ of 20 μM in LN229-HRE-AP cells, and with potential as a cancer therapy agent .

HY-101277

Vadadustat 5+ Cited Publications PG-1016548; AKB-6548	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor . Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo .

HY-106101

Echinomycin 10+ Cited Publications Quinomycin A; NSC-13502	HIF/HIF Prolyl-Hydroxylase Antibiotic Bacterial	Cancer
Echinomycin (Quinomycin A) is potent small-molecule and cell-permeable inhibitor of hypoxia-inducible factor-1 (HIF-1) DNA-binding activity. Echinomycin selectively inhibits the cancer stem cells (CSCs) with an IC₅₀ of 29.4 pM .

HY-111387

IDF-11774 5+ Cited Publications	HIF/HIF Prolyl-Hydroxylase	Cancer
IDF-11774 is a novel hypoxia-inducible factor α (HIFα)-1 inhibitor with an IC₅₀ of 3.65 μM.

HY-110266

GN44028 5+ Cited Publications	HIF/HIF Prolyl-Hydroxylase	Cancer
GN44028 is a potent and orally active hypoxia inducible factor (HIF)-1α inhibitor, with an IC₅₀ of 14 nM. GN44028 inhibits hypoxia-induced HIF-1α transcriptional activity without suppressing HIF-1α mRNA expression, HIF-1α protein accumulation, or HIF-1α/HIF-1β heterodimerization. GN44028 can be used in the research of cancers .

HY-101023

MK-8617 3 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
MK-8617 is an orally active pan-inhibitor of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) with an IC₅₀ of 1 nM for PHD2.

HY-107553

Chetomin 1 Publications Verification	HSP Apoptosis	Cancer
Chetomin, an active component of Chaetomium globosum, is a heat shock protein 90/hypoxia-inducible factor 1 alpha (Hsp90/HIF1α) pathway inhibitor. Chetomin is a potent, nontoxic non-small cell lung cancer cancer stem cells (NSCLC CSC)-targeting molecule .

HY-159644

Casdatifan AB521	HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
Casdatifan (AB521) is an orally active and selective allosteric small-molecule inhibitor of hypoxia-inducible factor 2α (HIF-2α). Casdatifan inhibits pro-tumor gene transcription by blocking the heterodimerization of HIF-2α with ARNT, and significantly suppresses tumor growth in clear cell renal cell carcinoma (ccRCC) models either as a monotherapy or in combination with agents such as Zimberelimab (HY-P99109). Casdatifan is applicable for the research of ccRCC .

HY-112144

TP0463518 1 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease Inflammation/Immunology
TP0463518 is an orally active, competitive pan-inhibitor of hypoxia-inducible factor prolyl hydroxylases PHD1/2/3. TP0463518 competitively inhibits human PHD1 (IC₅₀=18 nM), PHD2 (K_i=5.3 nM), and PHD3 (IC₅₀=63 nM), and targets monkey PHD2 with an IC₅₀ of 22 nM. TP0463518 inhibits PHD-catalyzed hydroxylation to stabilize HIFα, thereby upregulating erythropoietin (EPO) expression and enhancing intestinal iron absorption (such as increased DMT-1 and dCYTb expression), improving anemia. TP0463518 is mainly used for the research of renal anemia and inflammatory anemia .

HY-W016409

Ethyl 3,4-dihydroxybenzoate 1 Publications Verification Protocatechuic acid ethyl ester	HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) NO Synthase Autophagy Apoptosis	Metabolic Disease Cancer
Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .

HY-17412R

Minocycline hydrochloride (Standard)	Reference Standards Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase Apoptosis MDM-2/p53 Potassium Channel Calcium Channel	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Minocycline (hydrochloride) (Standard) is the analytical standard of Minocycline (hydrochloride). This product is intended for research and analytical applications. Minocycline hydrochloride is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline hydrochloride is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline hydrochloride shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline hydrochloride reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline hydrochloride inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-139287

M1002 2 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
M1002 is a **hypoxia-inducible factor-2 (HIF-2*) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors* .

HY-15672

FM19G11	HIF/HIF Prolyl-Hydroxylase	Neurological Disease Cancer
FM19G11 is a hypoxia-inducible factor-1-alpha (HIF-1α) inhibitor, and it inhibits hypoxia-induced luciferase activity with an IC₅₀ of 80 nM in HeLa cells. FM19G11 modulates other signaling pathways, including mTOR and PI3K/Akt/eNOS, when the HIF-1α pathway is inactivated under normoxic conditions .

HY-B2171A

Carubicin hydrochloride Carminomycin hydrochloride; Carminomicin I hydrochloride	Apoptosis	Infection Cancer
Carubicin hydrochloride is a microbially-derived compound. Carubicin hydrochloride is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin hydrochloride also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin hydrochloride has the potential for the research of cancer diseases .

HY-16187

EL-102	HIF/HIF Prolyl-Hydroxylase Apoptosis	Cancer
EL-102 is a hypoxia-induced factor 1 (Hif1α) inhibitor. EL-102 induces apoptosis, inhibits tubulin polymerisation and shows activities against prostate cancer. EL-102 can be used for the research of cancer .

HY-P10426

cyclo(CLLFVY)	HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
cyclo(CLLFVY) is an inhibitor for **hypoxia inducible factor-1 (HIF-1), with IC₅₀** of 19 μM (in U2OS) and 16 μM (in MCF-7). cyclo(CLLFVY) binds to the PAS-B domain of HIF-1α, inhibits HIF-1 dimerization and transcriptional activity. cyclo(CLLFVY) downregulates the expression of hypoxia response genes, such as VEGF and CAIX, exhibits antitumor against the HIF-1 associated cancers .

HY-168533

ZG-2305	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
ZG-2305 is a potent, orally active and selective factor inhibiting hypoxia-inducible factor (FIH) inhibitor with K_i values of 79.6, 2786 nM for FIH, PHD2, respectively. ZG-2305 increases the expression of EGLN3 gene. ZG-2305 decreases the cellular triglycerides levels and reduces lipid accumulation. ZG-2305 has the potential for the research of obesity and fatty liver disease .

HY-146144

HIF-IN-1	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-IN-1 (Compound 3c) is a hypoxia-inducible factor (HIF)-1 inhibitor. HIF-IN-1 suppresses HIF-1α protein accumulation without affecting the levels of HIF-1α mRNA. HIF-IN-1 shows no obvious cytotoxicity .

HY-136748

HIF-2α-IN-4 1 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-4 is a potent inhibitor of hypoxia inducible factor-2α (HIF-2α) translation, with an IC₅₀ of 5 μM. HIF-2α-IN-4 decreases both constitutive and hypoxia-induced HIF-2α protein expression. HIF-2α-IN-4 links its 5'UTR iron-responsive element to oxygen sensing .

HY-108697A

(Rac)-PT2399	HIF/HIF Prolyl-Hydroxylase	Cancer
(Rac)-PT2399 (Compound 10e), the racemate of PT2399, acts as a potent and specific hypoxia-inducible factor 2a (HIF-2α) inhibitor with an IC₅₀ of 0.01 μM .

HY-13426S

Roxadustat-d5	HIF/HIF Prolyl-Hydroxylase Ferroptosis	Cancer
Roxadustat-d₅ is deuterium labeled Roxadustat. Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin .

HY-16560S

Camptothecin-d5 Campathecin-d₅; (S)-(+)-Camptothecin-d₅; CPT-d₅	Isotope-Labeled Compounds Topoisomerase ADC Payload MicroRNA Influenza Virus Apoptosis Fungal Antibiotic	Infection Cancer
Camptothecin-d₅ is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM . Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells .

HY-17412AS

Minocycline-d6	Isotope-Labeled Compounds Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase Apoptosis MDM-2/p53 Potassium Channel Calcium Channel	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Minocycline-d₆ is deuterium labeled Minocycline (HY-17412A). Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-P10222

Cyclo(CRLLIF)	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CRLLIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 14.5 and 10.2 μM, respectively .

HY-112441

Prolyl Hydroxylase inhibitor 1	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Prolyl Hydroxylase inhibitor 1 (Compound 15i) is an orally active hypoxia inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitor with an IC₅₀ of 62.23 nM . Antianemia agent .

HY-18370

HIF-2α-IN-3	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-3, an allosteric inhibitor of **hypoxia inducible factor-2α (HIF-2α), exhibits an IC₅₀ of 0.4 µM and a K_D** of 1.1 µM. Anticancer agent .

HY-148264

Imdatifan HIF-2α-IN-7; NKT2152	HIF/HIF Prolyl-Hydroxylase	Infection Metabolic Disease Inflammation/Immunology Cancer
Imdatifan (HIF-2α-IN-7) is a hypoxia inducible factor 2α (HIF-2α) inhibitor. Imdatifan can inhibit HIF-2α with an EC₅₀ value of 6 nM. Imdatifan can be used for the research of various types of diseases including cancer, liver disease, inflammatory disease, pulmonary diseases and iron load disorders .

HY-141625

TRC160334	HIF/HIF Prolyl-Hydroxylase	Others
TRC160334 is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 can be used for the research of ischemia/reperfusion injury .

HY-17608R

Daprodustat (Standard) GSK1278863 (Standard)	Reference Standards HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Daprodustat (Standard) is the analytical standard of Daprodustat. This product is intended for research and analytical applications. Daprodustat (GSK1278863) is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor being developed for the treatment of anemia associated with chronic kidney disease.

HY-130264

HIF-2α-IN-2	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-2 is a hypoxia-inducible factors (HIF-2α) inhibitor extracted from patent WO2015035223A1, Compound 232, has an IC₅₀ of 16 nM in scintillation proximity assay (SPA) .

HY-13426R

Roxadustat (Standard) FG-4592 (Standard)	Reference Standards HIF/HIF Prolyl-Hydroxylase Ferroptosis	Cancer
Roxadustat (Standard) is the analytical standard of Roxadustat. This product is intended for research and analytical applications. Roxadustat is an orally active hypoxia-inducible factor (HIF) prolyl-hydroxylase (PHD) inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin .

HY-B2171

Carubicin Carminomycin; Carminomicin I	Apoptosis	Infection Cancer
Carubicin (Carminomycin) is a microbially-derived compound. Carubicin is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin has the potential for the research of cancer diseases .

HY-W747868

Molidustat sodium	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Molidustat sodium is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC₅₀ values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat sodium can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat sodium can be utilized in the research of renal anemia .

HY-101277S1

Vadadustat-13C6 PG-1016548-¹³C₆; AKB-6548-¹³C₆	Isotope-Labeled Compounds HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Vadadustat- ¹³C₆ (PG-1016548- ¹³C₆) is ¹³C labeled Vadadustat. Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor . Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo .

HY-179341

CHNQD-03301	HIF/HIF Prolyl-Hydroxylase	Cancer
CHNQD-03301 is an orally active hypoxia-inducible factor-1α (HIF-1α) inhibitor (IC₅₀ = 10.97 nM). CHNQD-03301 promotes the proteasomal degradation of HIF-1α protein, leading to its significant suppression. CHNQD-03301 can reverse HIF accumulation-induced angiogenesis and mitigate the HIF-induced erythrocytosis phenotype in zebrafish models. CHNQD-03301 can be used for the study of colon cancer .

HY-16560R

Camptothecin (Standard) Campathecin (Standard); (S)-(+)-Camptothecin (Standard); CPT (Standard)	Reference Standards Topoisomerase ADC Payload MicroRNA Influenza Virus Apoptosis Fungal Antibiotic	Infection Cancer
Camptothecin (Standard) (Campathecin (Standard)) is the analytical standard of Camptothecin (HY-16560). This product is intended for research and analytical applications. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells.

HY-N12041

Axl-IN-16	TAM Receptor HIF/HIF Prolyl-Hydroxylase	Cancer
Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression .

HY-17412S1

Minocycline-d6 sulfate	Isotope-Labeled Compounds Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase Apoptosis MDM-2/p53 Potassium Channel Calcium Channel	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Minocycline-d₆ sulfate is deuterated labeled Minocycline (HY-17412A). Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-17412S

Minocycline-d6 hydrochloride	Isotope-Labeled Compounds Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase Apoptosis MDM-2/p53 Potassium Channel Calcium Channel	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Minocycline-d₆ hydrochloride is deuterated labeled Minocycline hydrochloride (HY-17412). Minocycline hydrochloride is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline hydrochloride is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline hydrochloride shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline hydrochloride reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline hydrochloride inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-P10223

Cyclo(CRVIIF)	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CRVIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 65 and 123 μM, respectively .

HY-175521

HIF-1α-IN-8	HIF/HIF Prolyl-Hydroxylase IKK NF-κB Apoptosis Reactive Oxygen Species (ROS)	Inflammation/Immunology
HIF-1α-IN-8 is an orally active HIF-1α inhibitor, with an IC₅₀ of 2.02 μM. HIF-1α-IN-8 significantly suppresses the expression of inflammation factors of IL-6 and NO, reduces hypoxia-induced ROS production and apoptosis in C8-D1A cells. HIF-1α-IN-8 inhibits HIF-1α/IKKα/NF-κB signaling pathway and reduces the expression of blood-brain barrier permeability-related proteins. HIF-1α-IN-8 reduces brain water content and oxidative stress level in mice with high altitude cerebral edema (HACE) model. HIF-1α-IN-8 can be used for the study of high altitude cerebral edema (HACE) .

HY-141625A

TRC160334 sodium	HIF/HIF Prolyl-Hydroxylase	Others
TRC160334 sodium is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 sodium can be used for the research of ischemia/reperfusion injury .

Cat. No.	Product Name	Target	Research Area

HY-P10426

cyclo(CLLFVY)	HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
cyclo(CLLFVY) is an inhibitor for **hypoxia inducible factor-1 (HIF-1), with IC₅₀** of 19 μM (in U2OS) and 16 μM (in MCF-7). cyclo(CLLFVY) binds to the PAS-B domain of HIF-1α, inhibits HIF-1 dimerization and transcriptional activity. cyclo(CLLFVY) downregulates the expression of hypoxia response genes, such as VEGF and CAIX, exhibits antitumor against the HIF-1 associated cancers .

HY-P10222

Cyclo(CRLLIF)	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CRLLIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 14.5 and 10.2 μM, respectively .

HY-P10223

Cyclo(CRVIIF)	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CRVIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 65 and 123 μM, respectively .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-16560

Camptothecin 65+ Cited Publications Campathecin; (S)-(+)-Camptothecin; CPT	Infection Alkaloids Classification of Application Fields Quinoline Alkaloids Camptotheca acuminata Decne. Nyssaceae Plants Disease Research Fields	Topoisomerase ADC Payload MicroRNA Influenza Virus Apoptosis Fungal Antibiotic
Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM . Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells .

HY-W016409

Ethyl 3,4-dihydroxybenzoate 1 Publications Verification Protocatechuic acid ethyl ester	Arachis hypogaea L. Classification of Application Fields Leguminosae Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Source Classification	HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) NO Synthase Autophagy Apoptosis
Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .

HY-B2171A

Carubicin hydrochloride Carminomycin hydrochloride; Carminomicin I hydrochloride	Infection Quinones Microorganisms Classification of Application Fields Anthraquinones Phenols Polyphenols Disease Research Fields Source Classification	Apoptosis
Carubicin hydrochloride is a microbially-derived compound. Carubicin hydrochloride is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin hydrochloride also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin hydrochloride has the potential for the research of cancer diseases .

HY-B2171

Carubicin Carminomycin; Carminomicin I	Infection Quinones Microorganisms Classification of Application Fields Anthraquinones Phenols Polyphenols Disease Research Fields Source Classification	Apoptosis
Carubicin (Carminomycin) is a microbially-derived compound. Carubicin is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin has the potential for the research of cancer diseases .

HY-16560R

Camptothecin (Standard) Campathecin (Standard); (S)-(+)-Camptothecin (Standard); CPT (Standard)	Alkaloids Structural Classification Quinoline Alkaloids Camptotheca acuminata Decne. Nyssaceae Plants	Reference Standards Topoisomerase ADC Payload MicroRNA Influenza Virus Apoptosis Fungal Antibiotic
Camptothecin (Standard) (Campathecin (Standard)) is the analytical standard of Camptothecin (HY-16560). This product is intended for research and analytical applications. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells.

HY-N12041

Axl-IN-16	Natural Products Microorganisms Source Classification	TAM Receptor HIF/HIF Prolyl-Hydroxylase
Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression .

HY-N10330

7-Hydroxyneolamellarin A	Animals Phenols Source Classification	HIF/HIF Prolyl-Hydroxylase VEGFR
7-Hydroxyneolamellarin A is a natural product that could be derived from sponge Dendrilla nigra. 7-Hydroxyneolamellarin A is a potent hypoxia-inducible factor-1α (HIF-1α) inhibitor. 7-Hydroxyneolamellarin A attenuates the accumulation of hypoxia-inducible factor-1α (HIF-1α) protein and inhibits vascular epidermal growth factor (VEGF) transcriptional activity. 7-Hydroxyneolamellarin A can be used in research of cancer .

HY-W016409R

Ethyl 3,4-dihydroxybenzoate (Standard) Protocatechuic acid ethyl ester (Standard)	Structural Classification Arachis hypogaea L. Leguminosae Phenols Polyphenols Plants Source Classification	Reference Standards HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) NO Synthase Autophagy Apoptosis
Ethyl 3,4-dihydroxybenzoate (Standard) (Protocatechuic acid ethyl ester (Standard)) is the analytical standard of Ethyl 3,4-dihydroxybenzoate (HY-W016409). This product is intended for research and analytical applications. Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .

Cat. No.	Product Name	Chemical Structure

HY-13426S

Roxadustat-d5
Roxadustat-d₅ is deuterium labeled Roxadustat. Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin .

HY-16560S

Camptothecin-d5

Camptothecin-d₅ is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM . Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells .

HY-17412AS

Minocycline-d6

Minocycline-d₆ is deuterium labeled Minocycline (HY-17412A). Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-101277S1

Vadadustat-13C6
Vadadustat- ¹³C₆ (PG-1016548- ¹³C₆) is ¹³C labeled Vadadustat. Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor . Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo .

HY-17412S1

Minocycline-d6 sulfate

Minocycline-d₆ sulfate is deuterated labeled Minocycline (HY-17412A). Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-17412S

Minocycline-d6 hydrochloride

Minocycline-d₆ hydrochloride is deuterated labeled Minocycline hydrochloride (HY-17412). Minocycline hydrochloride is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline hydrochloride is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline hydrochloride shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline hydrochloride reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline hydrochloride inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-W654013

Minocycline-d7

Minocycline-d₇ is deuterium labeled Minocycline. Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-W778057

Ethyl 3,4-Dihydroxybenzoate-13C3

Ethyl 3,4-Dihydroxybenzoate- ¹³C₃ (Protocatechuic acid ethyl ester- ¹³C₃) is the ¹³C-labeled Ethyl 3,4-dihydroxybenzoate (HY-W016409). Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks